Executive Officers

Matthew W. Foehr , Chief Executive Officer

Matthew W. Foehr is President and Chief Executive Officer and a member of the Board of Directors of OmniAb, and has more than 25 years of pharmaceutical industry experience managing operations, technology development and global research and development programs. Mr. Foehr previously served as President and Chief Operating Officer at Ligand Pharmaceuticals from 2015 to 2022 and prior to that, served as Ligand’s Executive Vice President and Chief Operating Officer since 2011. Prior to joining Ligand, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GlaxoSmithKline. Following GSK’s acquisition of Stiefel in 2009, Mr. Foehr led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Mr. Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support, and Vice President of Global Supply Chain Technical Services. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation including Senior Vice President of Technical Operations and Vice President of Manufacturing. Mr. Foehr serves on the Board of Directors of Viking Therapeutics, Inc., a publicly-traded biotechnology company and served as a director of Ritter Pharmaceuticals, Inc. from 2015 until its merger with Qualigen Therapeutics, Inc. in 2020. Mr. Foehr received his BS degree in biology from Santa Clara University.

Kurt Gustafson, Chief Financial Officer

Kurt Gustafson has served as OmniAb’s Executive Vice President, Finance and Chief Financial Officer since March of 2022. Prior to joining OmniAb, Mr. Gustafson served as Executive Vice President and Chief Financial Officer of Spectrum Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, a position he held since 2013. Prior to joining Spectrum, Mr. Gustafson served as Vice President and Chief Financial Officer at Halozyme Therapeutics, Inc., a publicly traded biopharmaceutical company, where he was responsible for finance, information technology, facilities, and human resources. Before joining Halozyme in 2009, Mr. Gustafson worked at Amgen Inc. for over 18 years, ultimately serving there as Vice President, Finance, with responsibility for financial planning and cost accounting for worldwide manufacturing covering seven manufacturing sites. During his tenure at Amgen, Mr. Gustafson also served as Treasurer, Vice President, Finance and Chief Financial Officer of Amgen International based in Switzerland. Mr. Gustafson is currently a member of the Board of Directors of Xencor, Inc., a clinical stage biopharmaceutical company. Mr. Gustafson received a BA in Accounting at North Park University and an MBA from the University of California, Los Angeles.

Charles Berkman, JD, Chief Legal Officer and Secretary

Charles Berkman, JD has served OmniAb’s Chief Legal Officer since March of 2022. Previously, Mr. Berkman served as Senior Vice President, General Counsel and Secretary at Ligand Pharmaceuticals from 2018 to 2022 and prior to that as Ligand’s Vice President, General Counsel and Secretary from 2007 to 2018. Mr. Berkman joined Ligand in November 2001 as Associate General Counsel and Chief Patent Counsel. Prior to that, Mr. Berkman was an attorney at the international law firm of Baker & McKenzie and an attorney at the law firm of Lyon & Lyon, where he specialized in intellectual property law. Mr. Berkman earned a BS in Chemistry from the University of Texas and a JD from the University of Texas School of Law.